Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria...